Literature DB >> 19898447

How Tysabri survived.

Brady Huggett1.   

Abstract

Most drugs withdrawn from the market because of serious toxicities never make it back. But Biogen Idec succeeded in getting its multiple sclerosis (MS) drug Tysabri reintroduced in less than 16 months.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19898447     DOI： 10.1038/nbt1109-986

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


  2 in total

1.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

2.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245
  2 in total
  8 in total

1.  Novartis eyes oral MS drug as potential blockbuster.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2010-11       Impact factor: 54.908

2.  Biologic Therapies for Crohn's Disease: Update from the 2009 ACG Meeting.

Authors:  David G Binion
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

3.  Anti-CD20 antibody wows in multiple sclerosis.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2015-12-09       Impact factor: 54.908

4.  PML problems loom for Rituxan.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2010-02       Impact factor: 54.908

5.  Integrins and their extracellular matrix ligands in lymphangiogenesis and lymph node metastasis.

Authors:  Jie Chen; J Steven Alexander; A Wayne Orr
Journal:  Int J Cell Biol       Date:  2012-02-12

6.  Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.

Authors:  Igho J Onakpoya; Carl J Heneghan; Jeffrey K Aronson
Journal:  BMC Med       Date:  2015-02-05       Impact factor: 8.775

Review 7.  Integrins as Therapeutic Targets: Successes and Cancers.

Authors:  Sabine Raab-Westphal; John F Marshall; Simon L Goodman
Journal:  Cancers (Basel)       Date:  2017-08-23       Impact factor: 6.639

8.  Anti-integrin therapy for multiple sclerosis.

Authors:  Eiji Kawamoto; Susumu Nakahashi; Takayuki Okamoto; Hiroshi Imai; Motomu Shimaoka
Journal:  Autoimmune Dis       Date:  2012-12-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.